News

Public · Published

Travere Therapeutics, Inc. Stock 12‑Month Price Target Cut to $74.36, Implies 51% Upside

The average 12-month price target for Travere Therapeutics from 14 analysts fell to $74.36 from $75.21, with forecasts ranging from $62 to $90 per share. Based on the Nov. 2 closing price, the new target implies about 51% potential upside.

Published:

Updated:

What happened

The average 12-month price target for Travere Therapeutics from 14 analysts fell to $74.36 from $75.21, with forecasts ranging from $62 to $90 per share. Based on the Nov. 2 closing price, the new target implies about 51% potential upside.

Confirmed

Global impact / market context

A lower average target means analysts on balance see slightly less room for the stock to rise, even though they still expect a large gain. That trimmed expectation can affect how investors size their positions, since fair-value estimates guide whether they add to or reduce holdings.

Analyst inference

The target range of $62 to $90 shows analysts disagree widely on what the shares are worth. That wide spread, plus 14 Buys and one Hold, suggests most coverage remains positive but the expected gain depends heavily on which estimate an investor trusts.

Analyst inference

What to watch

  1. Watch whether the average target keeps drifting lower from $74.36, since a continued slide would signal analysts are trimming expectations rather than making a one-time adjustment. Confirmed
  2. Watch for any analyst moving from Buy to Hold, because even one downgrade among 15 would change the near-unanimous Buy consensus and could shift how investors view the stock. Proposed
  3. Watch whether the shares move toward the $62 low end of the range, since that would shrink the implied 51% upside and test whether analysts' targets still hold. Analyst inference

Evidence

  • Original source link unavailable